16-186 - Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Status: open

A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer

Treatment for Cervical Cancer

Contact Us Or call (251) 445-9834

Description

The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186

Sponsors

This trial is sponsored by Merck.

Providers Associated With This Trial

Principle Investigator

    Sub Investigators

    • Rocconi RodneyView Profile
      Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Associate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
    This link will open in a new tab or window.